Marker Therapeutics, Inc. (MRKR) News
Filter MRKR News Items
MRKR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MRKR News From Around the Web
Below are the latest news stories about MARKER THERAPEUTICS INC that investors may wish to consider to help them evaluate MRKR as an investment opportunity.
Marker Therapeutics inks $25M stock purchase agreement with Lincoln Park Capital FundMarker Therapeutics agreed to a $25 million stock purchase deal with Chicago-based institutional investor Lincoln Park Capital Fund to help advance clinical trials for some of its immunotherapy products. |
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 MillionHOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company has entered into a Common Stock Purchase Agreement (the "Agreement") for up to $25 million with Lincoln Park Capital Fund ("LPC"), a Chicago-based institutional investor and long-term |
Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic CancerHOUSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for MT-601, a multi-tumor-associated antigen (multiTAA)-specific T cell product tar |
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue EstimatesMARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Marker Therapeutics Reports Q3 2022 Operating and Financial ResultsCompany awarded $2 million U.S. FDA Orphan Products Grant to support Phase 2 ARTEMIS trial of its lead T cell therapy candidate MT-401 in patients with post-transplant AMLHOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported |
Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AMLAward to fund clinical study of Marker’s multi-antigen targeted T cell therapy for the treatment of post-transplant AML patients with minimal residual diseaseHOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company has been awarded a $2 mill |
Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines ConferenceHOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Peter L. Hoang, Marker’s President and Chief Executive Officer, will participate in a panel discussion titled, “CAR-T and Beyond: What Are the Next Generation Cell Therapies?,” at the Cantor Fitz |
Marker Therapeutics Reports Q2 2022 Operating and Financial ResultsHOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the second quarter ended June 30, 2022. “We are proud of our progress this year in advancing our Company-sponsored clinical program in AML, and earl |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayPre-market stock movers are the hot topic this morning as we cover all the latest news sending shares higher and lower on Monday! |